Effect of oral magnesium supplementation on insulin sensitivity and blood pressure in apparently healthy overweight adults: a randomised double-blinded controlled trial

Not Applicable

Completed

• Conditions: Overweight, obesity; Nutritional, Metabolic, Endocrine; Obesity

• Registration Number: ISRCTN92199360
• Lead Sponsor: TEI (Trace Elements Incorporated) Korea (South Korea)

Brief Summary

2009 results in https://pubmed.ncbi.nlm.nih.gov/19359148/ (added 08/04/2021)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2006-01-08
• Study Start: 2007-12-18
• Last Update Posted: 19 April 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 155

Inclusion Criteria

1. Aged 30 - 60 years
2. Body mass index greater than or equal to 23 kg/m^2
3. Have not taken any supplements or medications, including anti-diabetic drugs, anti-hypertensive drugs, steroids, or hormonal products, during the previous 4 weeks

Exclusion Criteria

1. Pregnant women
2. Those suffering from chronic illnesses, including:
2.1. Chronic liver and renal diseases
2.2. Severe bradycardia
2.3. Myasthenia gravis
2.4. Hypermagnesemia

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> 1. The HOMeostasis model Assessment of Insulin Resistance (HOMA-IR)<br> 2. Quantitative Insulin Sensitivity Check Index (QUICKI)<br> 3. Systolic BP<br> 4. Diastolic BP<br><br> Primary outcomes measured at baseline and 12 weeks (at the end of this study).<br>

Secondary Outcome Measures

Name	Time	Method
<br> 1. Lipids<br> 2. Serum trace minerals (magnesium, calcium, and phosphorus)<br><br> Secondary outcomes measured at baseline and 12 weeks (at the end of this study).<br>